NeuroSense Therapeutics Ltd.

NasdaqCM NRSN

NeuroSense Therapeutics Ltd. Free Cash Flow Per Share for the year ending December 31, 2023: USD -0.62

NeuroSense Therapeutics Ltd. Free Cash Flow Per Share is USD -0.62 for the year ending December 31, 2023, a 6.57% change year over year. Free cash flow per share is the free cash flow generated per share. Indicates investment potential based on cash flow generation.

NeuroSense Therapeutics Ltd. Free Cash Flow Per Share for the year ending December 31, 2022 was USD -0.67, a 16.99% change year over year.
NeuroSense Therapeutics Ltd. Free Cash Flow Per Share for the year ending December 31, 2021 was USD -0.80, a -121.02% change year over year.
NeuroSense Therapeutics Ltd. Free Cash Flow Per Share for the year ending December 31, 2020 was USD -0.36, a -19.52% change year over year.
NeuroSense Therapeutics Ltd. Free Cash Flow Per Share for the year ending December 31, 2019 was USD -0.30.

Key data

Date	Free Cash Flow Per Share	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)

NasdaqCM: NRSN

NeuroSense Therapeutics Ltd.

CEO	Mr. Alon Ben-Noon
IPO Date	Dec. 9, 2021
Location	Israel
Headquarters	Building B
Employees	18
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Robotics

Description

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Key trends

Past 5 years